新科学想法 › 学术文库 › 学术文献 › 浏览文献

Vascular Endothelial Growth Factor in Patients with Exudative Age-related Macular Degeneration Treated with Ranibizumab

yucloud 添加于 2012-10-30 16:15 | 1527 次阅读 | 0 个评论

作者
Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S
摘要
OBJECTIVES: To analyze the temporal correlations of vascular endothelial growth factor (VEGF) suppression, morphologic recurrence of choroidal neovascularization (CNV), and visual acuity loss in eyes with exudative age-related macular degeneration (AMD) treated with ranibizumab. DESIGN: Nonrandomized, prospective, clinical study. PARTICIPANTS: Forty-seven eyes of 47 patients with exudative AMD undergoing intravitreal ranibizumab injections. METHODS: Aqueous humor specimens were taken before each intravitreal ranibizumab injection. Visual acuity testing, spectral domain optical coherence tomography (SD-OCT), and fundoscopy were performed before each injection. Vascular endothelial growth factor A was measured by Luminex multiplex bead analysis (Luminex Inc., Austin, TX). MAIN OUTCOME MEASURES: Intraocular VEGF concentration, recurrence of CNV activity shown by SD-OCT, and vision loss. RESULTS: Ranibizumab resulted in complete VEGF suppression within a mean period of 37.8 days (standard deviation [SD] +/- 4.8 days; range, 26-49 days). Recurrences of CNV activity as determined by SD-OCT occurred 93.7 days (SD +/- 69.9 days; range, 57-368 days) after the last ranibizumab treatment. The VEGF levels were never suppressed when a recurrence occurred. Functional recurrence (visual acuity) occurred 114.3 days (SD +/- 81.4 days; range, 57-398 days) after previous treatment. The VEGF levels did not differ significantly between baseline and recurrence (69.3 pg/ml vs. 74.14 pg/ml; 95% confidence interval, -18.87 to 9.12). CONCLUSIONS: A monthly intravitreal injection of 0.5 mg ranibizumab yields a durable VEGF inhibition. The recurrences of CNV as determined by SD-OCT are always preceded by a loss of intraocular VEGF suppression and usually followed by loss of visual acuity in the further course. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
详细资料
- 文献种类: Journal Article
- 期刊名称: Ophthalmology
- 期刊缩写: Ophthalmology
- 期卷页: 2012年第119卷第10期 2082-2086页
- 地址: Department of Vitreoretinal Surgery, Center of Ophthalmology, University of Cologne, Cologne, Germany
- ISBN: 0161-6420
学科领域生物医药 » 药学
相关链接 DOI URL
yucloud 的文献笔记订阅